SpainSpain

Spanish start up to develop therapeutic HPV vaccine

18.06.2008

A Madrid – About 70% of all women will become infected with papilloma viruses (HPV) at least once in their lifetime. Now, the Spanish vaccine specialist Chimera Pharma SL (Madrid) has signed an exclusive licensing and cooperation agreement with the German Cancer Research Centre (DKFZ) in Heidelberg. Under the agreement, the two partners will develop, a therapeutic vaccine against cervical cancer to prevent women who are already infected with HPV from developing cancer, and to eradicate existing cancer prestages. Chimera has got exclusive world-wide rights to commercialise thevaccine.

Huge market promise

The market for a vaccine that kills the cancer-causing virus subtypes seems to be extremely promising. Sanofi-Pasteur MSD, which licensed IP from Chimera’s German cooperation partners under Prof. Harald zur Hausen and Dr. Angel Cid-Arregui, has made EUR1.3bn revenues with the prophylactic HPV vaccine Gardasil® since its market launch in June 2006.
Together with our Spanish partners, we will develop a protein vaccine against HPV16 and HPV18, which are linked to cervical cancer,” Cid-Arregui told EuroBiotechNews. The vaccine will be based on fusion proteins of three HPV envelope protein domains with the HBSAg envelope protein of the Hepatitis-B virus, which forms empty immunogenic virus envelopes. In addition to this, the virus shells can transport further proteins that stimulate the immune system.
“Similar to our patented (US-PTO 7,201,908) vaccine candidate, we have demonstrated the preclinical efficacy of our new compound,” says Cid-Arregui. The young Spanish company – part of Madrid-based Grupo Bionostra – is currently beginning toxicological studies, and is planning to establish GMP production by February, and to file an application for clinical development by summer 2009. Like many biotech companies that develop compounds to Phase 2 for outlicensing to big pharma, Chimera currently does not have the resources for full clinical development. Thus, at the moment outlicencing to a big pharma company seems the most probable exit

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/spanish-start-up-to-develop-therapeutic-hpv-vaccine.html

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF137.5%
  • CELLECTIS (F)13.63 EUR103.4%
  • ADDEX (CH)4.29 CHF92.4%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3576.8%
  • GW PHARMACEUTICALS (UK)444.50 GBP828.4%
  • IXICO (UK)55.50 GBP320.5%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.92 EUR-72.4%

No liability assumed, Date: 09.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics